Friday, September 25, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1semaglutideselect trialobesitynovo nordisk

SELECT analysis finds baseline traits cannot predict semaglutide weight loss

Median peak weight loss was 12.5% after a median 19 months among 7,594 participants treated for at least one year.

MH
By Maren Holt · Senior Reporter, GLP-1
Sep 23 20:00 ETSource: Diabetes care

The wire

  1. 01In this prespecified SELECT analysis in Diabetes Care, the full predictor model explained under 10% of variability in peak percentage body weight loss; female sex drove 85.3% of that model.
  2. 02Clinicians cannot tell patients at initiation how much weight they will lose; dose mattered, with median peak loss of 13.3% at 2.4 mg versus 6.0% at 0.24 mg.
  3. 03The cohort was older, 72% men, with atherosclerotic disease and without diabetes, limiting generalizability to broader obesity populations.

From the source

Predictors of Peak Body Weight Loss With Semaglutide in the SELECT Trial

Diabetes care · 2026 Sep 24 · Lingvay I, Kushner RF, Kaul U et al.

Read at pubmed.ncbi.nlm.nih.gov
PeptiPrescribed peptides from $99/moSee all →